(c) 2024 PillSync.com

24 HR quetiapine 200 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Quetiapine extended-release tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia Quetiapine extended-release tablets are indicated for the treatment of Schizophrenia. The efficacy of quetiapine extended-release tablets in Schizophrenia was established in one 6-week and one maintenance trial in adults with Schizophrenia. Efficacy was supported by three 6-week trials in adults with Schizophrenia and one 6-week trial in adolescents with Schizophrenia (13 to 17 years) treated with quetiapine tablets [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder Quetiapine extended-release tablets are indicated for the acute treatment of manic or mixed episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of quetiapine extended-release tablets in manic or mixed episodes of Bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with Bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with Bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 to 17 years) with manic episodes associated with Bipolar I disorder treated with quetiapine tablets [see Clinical Studies (14.2) ]. Quetiapine extended-release tablets are indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of quetiapine extended-release tablets was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with quetiapine tablets [see Clinical Studies (14.2) ]. Quetiapine extended-release tablets are indicated for the maintenance treatment of Bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with Bipolar I disorder treated with quetiapine tablets. The effectiveness of monotherapy for the maintenance treatment of Bipolar I disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2) ]. 1.3 Adjunctive Treatment of Major depressive disorder (MDD) Quetiapine extended-release tablets are indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of quetiapine extended-release tablets as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment [see Clinical Studies (14.3) ]. 1.4 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I disorder Pediatric Schizophrenia and Bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric Schizophrenia, symptom profiles can be variable, and for Bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric Schizophrenia and Bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric Schizophrenia and Bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

sciegen pharmaceuticals, inc


4 years ago OVAL YELLOW 382 24 HR quetiapine 200 MG Extended Release Oral Tablet

OVAL YELLOW 382

4 years ago OVAL YELLOW 382 24 HR quetiapine 200 MG Extended Release Oral Tablet

382 OVAL YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING 50 mg Tablets peach, film coated, capsule-shaped, biconvex embossed tablet with “380” on one side and plain on the other are supplied in Bottles of 30 tablets: NDC 50228-380-30 Bottles of 60 tablets: NDC 50228-380-60 Bottles of 1,000 tablets: NDC 50228-380-10 150 mg Tablets white, film coated, capsule-shaped, biconvex embossed tablet with “381” on one side and plain on the other are supplied in Bottles of 30 tablets: NDC 50228-381-30 Bottles of 60 tablets: NDC 50228-381-60 Bottles of 1,000 tablets: NDC 50228-381-10 200 mg Tablets yellow, film coated, capsule-shaped, biconvex embossed tablet with “382” on one side and plain on the other are supplied in Bottles of 30 tablets: NDC 50228-382-30 Bottles of 60 tablets: NDC 50228-382-60 Bottles of 1,000 tablets: NDC 50228-382-10 300 mg Tablets pale yellow, film coated, capsule-shaped, biconvex embossed tablet with “383” on one side and plain on the other are supplied in Bottles of 30 tablets: NDC 50228-383-30 Bottles of 60 tablets: NDC 50228-383-60 Bottles of 500 tablets: NDC 50228-383-05 400 mg Tablets white, film coated, capsule-shaped, biconvex embossed tablet with “384” on one side and plain on the other are supplied in Bottles of 30 tablets: NDC 50228-384-30 Bottles of 60 tablets: NDC 50228-384-60 Bottles of 500 tablets: NDC 50228-384-05 Store

QUETIAPINE extended-release tablets at 25ºC (77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [See USP Controlled Room Temperature].


More pills like OVAL 382












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site